Immunoglobulin G was given intravenously (IVIgG) to pregnant women (27 to 36 weeks gestation) with signs of chorioamnionitis who were at risk for preterm delivery. Twenty-four patients received antibiotics alone (control group). Twenty-seven patients received the same antibiotics in combination with IVIgG, either 12 gm in 12 hours (low IVIgG dosage) or 24 gm on each of 5 consecutive days (high IVIgG dosage). Transplacental passage of IVIgG was shown to be a function of gestational age and of dose. Up to the thirty-second week of gestation, IgG infusions had no effect on IgG concentrations in cord sera. After that time, cord serum IgG levels were significantly higher in the high-dose group compared with the low-dose and control groups. All four subclasses of IgG, and two different antibodies present in the IVIgG preparation passed from the mother to the fetus. Thus the infused IgG mimicked the transplacental passage of endogenous IgG.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-3476(86)80132-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prenatal toxicity of L-mimosine in Wistar rats.
Toxicon
January 2025
Department of Pathology, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, S.P., Brazil; Institute of Environmental, Chemical and Pharmaceutical Sciences, Federal University of São Paulo (ICAQF-UNIFESP), Diadema, S.P., Brazil. Electronic address:
L-Mimosine is the main active component of the plant Leucaena leucocephala. Due to its metal-chelating mechanism, it interacts with various metabolic pathways in living organisms, making it a potential pharmacological target, although it also leads to toxicity. The present study aimed to investigate the transplacental passage of L-mimosine and its effects on embryofetal development.
View Article and Find Full Text PDFPregnancy in People With Cystic Fibrosis Treated With Highly Effective Modulator Therapy.
Obstet Gynecol
January 2025
Division of Pulmonary and Critical Care Medicine, the Division of Pediatric Pulmonology, and the Division of Maternal Fetal Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Article Synopsis
- New medications called highly effective modulator therapy are improving health for many people with cystic fibrosis (CF), leading to more pregnancies among these individuals.
- The safety of these medications during pregnancy is unclear, as limited data show potential risks, such as health declines in patients when therapy is stopped and possible cataract development in offspring.
- Ongoing studies are expected to shed light on these safety concerns, highlighting the importance of thorough counseling for people with CF considering pregnancy.
Gestational Pemphigoid-From Molecular Mechanisms to Clinical Outcomes: A Case Report and Review of Literature.
Life (Basel)
November 2024
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Gestational pemphigoid is a rare, autoimmune, subepidermal bullous disease with an incidence of 1 in 50,000 pregnancies, displaying itself through pruritic erythema and urticarial papules and plaques that evolve into tense bullae. Histopathological findings consist of subepidermal vesicles with perivascular eosinophils and lymphocytes, and direct immunofluorescence reveals C3 complement and, more rarely, IgG in a linear band along the basement membrane. The course is usually self-limiting within 6 months after delivery but, later, can be triggered by subsequent pregnancies, menstruation, or treatment with oral contraceptives.
View Article and Find Full Text PDFAlloimmunization in Pregnancy: Implications for the Fetus and Neonate.
Neoreviews
November 2024
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Evanston Hospital - Endeavor Health, University of Chicago Pritzker School of Medicine, Evanston, IL.
Article Synopsis
- Blood group alloimmunization happens when a pregnant woman develops antibodies against a blood type that her fetus has but she doesn't, usually due to fetal-maternal bleeding or blood transfusions.
- To prevent maternal alloimmunization, it's crucial to implement effective strategies before antibodies are formed, as this can lead to serious complications for the fetus.
- Proper management of alloimmunization in pregnant patients should follow established protocols, utilizing current evaluation and treatment methods to ensure the safety of both the mother and the baby.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!